SAN ANTONIO, Tex. (EGMN) - Adjuvant therapy with aromatase inhibitors for postmenopausal women with estrogen receptor-positive breast cancer significantly decreases the risk of recurrent disease, compared with tamoxifen, whether given as initial monotherapy or after several years of tamoxifen, results of two meta-analyses suggest.Aromatase inhibitors (AIs) produced significantly lower recurrence rates, compared with tamoxifen, in both cohorts, which together included more than 18,000 women. In cohort...